Navigation Links
Companion Diagnostics Market Report - Streamlining Drug Development and Advancing Personalized Medicine
Date:8/6/2013

DUBLIN, August 6, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/hkmzx8/companion) has announced the addition of the "Companion Diagnostics - Streamlining Drug Development and Advancing Personalized Medicine" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk.

Companion diagnostics can allow for a specific patient population to be identified which will ensure those patients who are most likely to respond are recruited for clinical trials and receive the therapy once the product is launched. Companion diagnostics can help to rationalize treatment decisions, with specifics such as accurate dosing, risks of adverse events and diagnostics being made possible through these tests. Through the use of companion diagnostics, the right treatment can be delivered to the right patient at the right time, delivering greater value and optimizing healthcare resource utilization.

Oncology has been the most active arena for companion diagnostics but, as research has advanced and new diagnostics developed, applications in other therapy areas are being discovered and established.

The report, Companion Diagnostics - Streamlining Drug Development and Advancing Personalized Medicine was written to support both the biopharmaceutical and diagnostic industries better understand the current challenges involved in developing products with a companion diagnostic, as well as the opportunities that will exist in the future. Recent success stories are identified and analyzed, and insights are provided throughout the study to support pharmaceutical & diagnostic strategic planning needs.

Key Reasons to Purchase

- This report provides an overview of advantages offered by companion diagnostics from early clinical development through to product launch and ongoing use in the patient population

- Understand what personalized medicine and companion diagnostics are and how these are expected to change the face of disease management

- Enables you to understand some of the key challenges faced during the development of companion diagnostics and recommendations on how to overcome them

- Provides an in-depth analysis of key case studies highlighting the successful application of companion diagnostics and how this has impacted company activities

- Gain insight into which pharmaceutical companies are leading the way in the development and application of companion diagnostics while assessing the key partnerships in place with diagnostics companies driving this sector forward

Key Topics Covered:

1. Executive summary

2. Methodology

3. Personalized medicine and companion diagnostics
- Personalized medicine overview
- What are biomarkers?
- What are companion diagnostics?

4. Advantages of companion diagnostics
- A more targeted patient population
- Focused drug development
- Rationalized treatment decisions
- Pharmacoeconomic advantages

5. Challenges in the development of companion diagnostics
- Logistical challenges
- Strategic business challenges
- Financial risks
- Regulatory challenges

6. Case studies
- Roche - leading the way with companion diagnostics
- Biogen Idec - a diagnostic to mitigate risk
- Xalkori - a sign of things to come?

7. A look to the future
- Companion diagnostics - a prerequisite to approval?
- A world beyond oncology
- Companies leading the way

For more information visit http://www.researchandmarkets.com/research/hkmzx8/companion.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Companion Diagnostics Market, 2012-2023
2. Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart Wins Silver at Medical Design Excellence Awards
3. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
4. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
5. Epizyme to Partner to Develop DOT1L Companion Diagnostic
6. SynCardias Companion 2 Driver Named a Finalist in the Medical Design Excellence Awards
7. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
8. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
9. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
10. The Complete Guide to Companion Diagnostics: Market Environment Products and Companies
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
(Date:7/28/2017)... CHICAGO, July 28, 2017 Hill-Rom Holdings, Inc. ... fiscal third quarter ended June 30, 2017, and updated ... For the fiscal third quarter, ... to $0.68 per diluted share in the prior-year period. ... of $0.39 per diluted share primarily related to the ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... ... luxurious collection of unique masks and serums that perfectly fuse the beauty of ... advancements, at the 2017 Indie Beauty Expo on August 23rd & 24th in ...
(Date:8/22/2017)... ... 2017 , ... The old adage “you are what you ... healthy foods. But this well-known piece of nutrition advice ignores that an individual’s ... not only on properties of the food but also on properties of the ...
(Date:8/22/2017)... , ... August 22, 2017 , ... ... pleased to announce the addition of Zack Tisch as the firm’s new Consulting ... KLAS-ranked healthcare IT consulting firm’s national accounts, from assisting clients with initial vendor ...
(Date:8/22/2017)... CA (PRWEB) , ... August 22, 2017 , ... ... cycle management (RCM) solutions, announced recently the availability of a new professional fee ... in appreciation for their service to the healthcare industry. E/M coding is complex ...
(Date:8/22/2017)... DFW Metroplex, TX (PRWEB) , ... August 22, 2017 , ... Five Star Glass is ... They provide repair and replacement of auto glass for most makes and models, in ... area in the USA. , They have been a family owned business for the ...
Breaking Medicine News(10 mins):